An 8‐year‐old girl with a papule on her cheek

Fontecilla, Natalia M.; Kent, Rhett A; Marathe, Kalyani

doi:10.1111/pde.13469

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Syringocystadenoma papilliferum: Syringocystadenoma papilliferum (SCAP), also known as papillary syringoadenoma, is a rare adnexal tumor that arises from the apocrine and eccrine glands. Whereas SCAP is a benign tumor, its malignant counterpart is syringocystadenocarcinoma papilliferum, which should be considered on histopathologic evaluation (Fontecilla et al, 2018). SCAP most commonly presents as a verrucous plaque or nodule located on the scalp or face in a child or young adult.…”

Section: Discussion Of Incorrect Answersmentioning

confidence: 99%

Cells to Surgery Quiz: August 2021

Akhtar

Levin²,

Rajabi‐Estarabadi

et al. 2021

Journal of Investigative Dermatology

View full text Add to dashboard Cite

What is false about the management and/or prognosis of melanoma? a. Some studies have found that the nodular melanoma histologic subtype is an independent risk factor for disease-related death.b. Melanoma occurring in patients aged <20 years has been reported to have a higher incidence of lymph node metastasis than that occurring in other age groups.c. Tumor mitotic rate is utilized as a primary tumor staging criterion in the current American Joint Committee on Cancer melanoma staging system.d. Surgical margins wider than 2 cm have not been demonstrated to improve patient outcomes.e. In previously untreated patients with advanced melanoma, combined administration of nivolumab and ipilimumab has been shown to improve survival compared with single-agent treatment with either nivolumab or ipilimumab. 3. Emran et al. (2021) report the result of dual targeting of BET and CDK9 proteins in melanoma cells in vitro and in vivo. All of the following are consistent with their findings except: a. High expression of BET and CDK9 proteins are associated with an adverse prognosis in patients with melanoma. b. Combined BET inhibitor (BETi) and CDK9 inhibitor (CDK9i) treatment markedly reduced the growth of human melanoma cells in the spheroid model. c. BETis and CDK9is induce apoptosis in melanoma cells associated with mitochondrial depolarization and downregulation of anti-apoptotic proteins BCL2, BCLXL, and MCL1. d. Drug combination downregulated phosphorylated protein kinase B (Akt) (S473), and Akt targets mTOR and phosphorylated S6K in C002M, C057M, and C013M cell lines.e. Cell death induced by the combination of drugs does involve pyroptosis.

show abstract

Section: Discussion Of Incorrect Answersmentioning

confidence: 99%

Cells to Surgery Quiz: August 2021

Akhtar

Levin²,

Rajabi‐Estarabadi

et al. 2021

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…The treatment of choice of SP is surgical excision. However, recurrence is common [1, 2, 5]. Our case was treated by surgical excision, with no recurrence until the time of the report.…”

Section: Discussionmentioning

confidence: 99%

“…The cause of SP is not clear. One-third of SP arises in nevus sebaceous [1, 2]. BRAF V600E mutation or activating mutations in HRAS (or less often KRAS) have been reported in sporadic forms, whereas nevus sebaceous carries the same HRAS mutation as the underlying nevus [1].…”

Section: Introductionmentioning

confidence: 99%

“…The most common location is the scalp and face. It rarely occurs on the nipple, breast, genitalia, eyelids, and extremities [1-3]. SP can be single or multiple.…”

Section: Introductionmentioning

confidence: 99%

“…However, in rare cases, SP may convert into a malignant lesion [1]. SP is common during childhood or early adulthood and occurs as asymptomatic slowly growing crusted reddish papule or plaque.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Syringocystadenoma Papilliferum: A Case Report and Review of the Literature

et al. 2019

View full text Add to dashboard Cite

Syringocystadenoma papilliferum is a very rare, benign adnexal tumor that originates from the apocrine sweat glands. Herein, we report a 25-year-old male who presented with a 10-year history of an asymptomatic slowly growing skin lesion on his face. Skin examination revealed a solitary rounded 3 × 3 cm erythematous plaque with central crustation on the right side of his face. Punch skin biopsy was taken from the lesion. The epidermis showed downward papillomatous extensions. The dermis showed multiple epithelial sheets and dilated ducts that were lined by columnar cells. On the basis of the above clinicopathological findings, the diagnosis of syringocystadenoma papilliferum was made. The patient was reassured and referred to a surgeon for surgical excision of the lesion.

show abstract

Syringocystadenoma papilliferum: case series and review of the literature

Gorji,

Hamilton,

Reyes

et al. 2023

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Syringocystadenoma papilliferum (SCAP) is a rare, hamartomatous tumor of the apocrine glands, which typically manifests in the head and neck region. We present a case of 60-year-old male with a several-year history of the lesion located on the abdominal wall and a second case of a 58-year-old male with a history of a slow-growing lesion located on the tragus. Despite varying presentations and locations, both patients were identified to have SCAP on pathological evaluation. Appropriate treatments of SCAP range from CO2 laser treatment to surgical excision; we recommend surgical excision due to the risk of malignant transformation.

show abstract

An 8‐year‐old girl with a papule on her cheek

Cited by 5 publications

References 7 publications

Cells to Surgery Quiz: August 2021

Cells to Surgery Quiz: August 2021

Syringocystadenoma Papilliferum: A Case Report and Review of the Literature

Syringocystadenoma papilliferum: case series and review of the literature

Contact Info

Product

Resources

About